Searchable abstracts of presentations at key conferences in endocrinology

ea0090p167 | Pituitary and Neuroendocrinology | ECE2023

Somatostatin analogue treatment is associated with lack of progression of pNETs <20mm in size in patients with MEN1

Frizelle Isolda , Velusamy Anand , McGowan Barbara , Breen Louise , Duncan Emma , Izatt Louise , Christodoulou Dimitra , Joshi Mamta , Paul Carroll

Introduction: Pancreatic neuroendocrine tumours (pNETs) are the main cause of mortality in patients with multiple endocrine neoplasia type 1 (MEN1). The CLARINET study demonstrated that somatostatin analogue treatment improved progression free survival in patients with enteropancreatic NETs but little is known about the role of SSA in preventing progression of pNETs in MEN1 (1). Many centres have started using SSA treatment in MEN1 patients with enlarging pNETs or tumours &#62...

ea0063p427 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

Genetic mutations in bladder paragangliomas - not just SDHB-related disease

Anandappa Samantha , Breen Louise , Thurairaja Ramesh , Christodoulou Dimitra , Jacques Audrey , Velusamy Anand , McGowan Barbara , Izatt Louise , Carroll Paul

Bladder Paragangliomas (PGLs) are rare forms of neuroendocrine tumours arising from sympathetic paraganglionic tissue. They account for <1% of all Pheochromocytomas and Paragangliomas (PPGLs) and < 0.06% of all bladder tumours. All patients with PPGLs are recommended to be considered for genetic testing as ~ 40% of PPGLs are associated with a germline mutation, even if there is no prior family history of disease. Identifying an inherited PPGL predisposition has importa...

ea0065p133 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Tumour detection and outcomes of surveillance screening in SDHB and SDHD mutation carriers

White Gemma , Masucci Michael , Anandappa Samantha , Joshi Mamta , McGowan Barbara , Obholzer Rupert , Jacques Audrey , Christodoulou Dimitra , Izatt Louise , Velusamy Anand , Carroll Paul

Background: Pathogenic variants in genes encoding Succinate Dehydrogenase subunits B and D (SDHB/SDHD) predispose to Phaeochromocytoma and Paraganglioma (PPGL). Cascade genetic screening identifies relatives at risk and allows surveillance screening to enable early detection of PPGLs.Methods: Retrospective analysis of genetic databases and hospital records between January 2000 and December 2018 identified relatives carrying SDHB and <em...

ea0094op7.2 | RET and Endocrine Cancer | SFEBES2023

Peptide receptor radiotherapy (prrt) for well- differentiated metastatic paraganglioma and phaeochromocytomas (ppgl)

Frizelle Isolda , Velusamy Anand , McGowan Barbara , Breen Louise , Izatt Louise , Touska Philip , Christodoulou Dimitra , Eftychiou Nicolas , Hassan Fahim-ul , Carroll Paul

Introduction: Pheochromocytoma and Paraganglioma (PPGL) are neuroendocrine tumours arising from chromaffin cells in the adrenal medulla or ganglia in the autonomic nervous system. ~40% of PPGL arise due to germline mutation (commonly SDHx) and sporadic tumours frequently have causative somatic mutations. 15-20% of PPGL behave in a malignant manner. ~95% PPGL express somastostatin receptors and are GaDOTATATE avid. Lutathera® is a commercially available PR...

ea0094p312 | Adrenal and Cardiovascular | SFEBES2023

The investigation and management of adrenal incidentalomas at guy’s and St Thomas’s NHS foundation trust

Desai Nirali , Gowrishankar Shravan , Hodson Alexander , Santucci Catherine , Demel Isabel , Zuckerman Benjamin , Armonis Panagiotis , Christodoulou Dimitra , Velusamy Anand , Carroll Paul , Saqib Aaisha

Background: Rapid improvements in imaging have led to a 10-fold increase in the incidence of adrenal incidentalomas (AIs) over the past two decades. Delays in the diagnostic evaluation of AIs are associated with patient anxiety and significant burden on medical resources. We retrospectively audited the investigation and management of AIs at Guy’s and St Thomas’s NHS Foundation Trust (GSTT).Methods: Patients wit...